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Summary
Objective: To determine the roles of insulin-like growth factor (IGF) and IGF-binding protein (IGFBP) in the pathogenesis of osteoarthritis (OA).
Design: Cartilage tissues were obtained from the femoral heads of patients with OA, and those from patients with femoral neck fractures were
used as a control. The expression of IGFBP-3, -4, and -5 was examined using immunohistochemistry and in situ hybridization, and IGF-I and
IGF-I receptors were also immunohistochemically detected. The percentages of positive chondrocytes were determined by counting the total
number of chondrocytes over the area of the surface, middle, and deep zones of the cartilage.
Results: There was a marked increase in the percentage of positive chondrocytes in all IGFBPs on protein and messenger RNA levels for OA
compared to that of the control cartilage. Furthermore, enhanced expression of IGFBPs and the IGF-I/IGF-I receptor was positively correlated
with the histologic score for cartilage lesions.
Conclusion: Up-regulation of IGFBPs as well as IGF-I and its receptor was observed for OA cartilage tissue, suggesting the involvement of
IGFBPs in the pathogenesis of OA.
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International
Cartilage
Repair
SocietyIntroduction
Osteoarthritis (OA) is characterized by degeneration of the
cartilagematrix andgraduallyprogresseswithout repair of the
damaged tissue, leading to functional disability of the joints.
No effective therapy for protecting cartilage from degenera-
tion has yet beenestablished. Theetiology of the diseasehas
not been fully understood, but aging and mechanical stress
are considered to be possible associated factors1.
Joint destruction is caused by an imbalance between the
synthesis and degradation of the cartilage matrix. For the
metabolism of cartilage matrix, interleukin (IL)-1b and tumor
necrosis factor (TNF-a) act as destructive cytokines2, while
insulin-like growth factor (IGF)-I and members of the trans-
forming growth factor-b family act as growth promoting
factors3,4. These negative and positive factors of matrix
metabolism are produced by chondrocytes and act in
a paracrine and/or autocrine fashion5. In OA, elevated levels
of IGF-I occur in the synovial ﬂuids6,7, along with the
increased expression of IGF-I in OA chondrocytes8,9.
Moreover, expression of the IGF-I receptor in OA cartilage
is normal or increased10,11. These ﬁndings led us to assume
the involvement of IGF-I in the pathogenesis ofOA.However,
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reported for experimental arthritis induced by the injection
of zymosan intomurine knee joints12 or for patientswithOA13.
Until now, six IGF-binding proteins (IGFBP-1 to -6), which
bind to IGF-I or IGF-II with high afﬁnity14, have been
discovered in the serum. In addition, IGFBP-2 to -5 are
synthesized and secreted by human articular chondrocytes in
vitro15. In the synovial ﬂuid of OA patients, elevated levels of
IGFBP-3 and -4 expression can be observed by Western
ligand blotting methods16, and the increased expression of
IGFBP-3 and -5 messenger RNA (mRNA) in OA chondro-
cytes can be seen byReverse Transcription (RT)-quantitative
polymerase chain reaction (PCR)15. Since IGF-I has a greater
afﬁnity for IGFBPs than its receptor, these results suggest that
the enhanced production of IGFBP-3, -4, or -5 may be
involved in thepathogenesis ofOAbydecreasing theeffective
concentration of IGF-I. However, little is known about the
cellular expression pattern of IGFBPs in OA cartilage.
In this study, we examined the expression of IGFBP-3, -4
and -5 in decalciﬁed tissue sections of OA and normal
cartilage at the transcript and protein level using in situ
hybridization (ISH) and immunohistochemistry (IHC), re-
spectively. Additionally, IGF-I and IGF-I receptors were
immunohistochemically detected. We found that the expres-
sion of IGFBP-3 to -5, as well as IGF-I and its receptor was
signiﬁcantly increased in OA cartilage, compared to that of
normal aged cartilage, suggesting involvement of the of IGF-
axis in the pathogenesis of OA.9
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CARTILAGE SPECIMENS
Human articular OA cartilage specimens were obtained
from the femoral heads of 10 female patients (mean age of
55, range of 43e72) while undergoing total hip replacement
with informed consent. The diagnosis of OA was based on
clinical and radiologic evaluations17. As a control, aged
cartilage tissue was obtained from the femoral heads of 10
female patients (mean age of 76, range of 51e85) with
a femoral neck fracture while receiving a hip prosthesis. All
specimens were immunohistologically examined, while six
from the OA group and ﬁve from the control group were
examined using ISH.
TISSUE PREPARATION
Full thickness pieces of cartilage were obtained from the
weight bearing area of the joint immediately after surgery.
The samples were then ﬁxed in 4% paraformaldehyde
(PFA) in phosphate-buffered saline (PBS) pH 7.4 at 4(C for
12 h, decalciﬁed with 10% ethylenediaminetetraacetic acid
(EDTA) at 4(C for 5e7 days and embedded in parafﬁn as
previously detailed18. The tissue blocks were next cut into
ﬁve-micron-thick sections, mounted on aminopropyltriethox-
ysilane-coated glass slides (Matsunami, Tokyo, Japan) and
used for the following experiments.
HISTOLOGIC GRADING
The sections were stained with hematoxylin and eosin,
Safranin-O and Fast Green for histological examination.
The severity of the OA cartilage lesions was determined
using the histologic/histochemical scores described by
Mankin et al.19; loss of Safranin-O staining (0e4), cellular
changes (0e3), invasion of a tidemark by blood vessels
(0e1), and structural changes (0e6), where 0 indicates the
state of normal cartilage and 14 indicates the most severe
histological change (Table I).
IMMUNOHISTOCHEMICAL STUDIES
The parafﬁn-embedded sections were deparafﬁnized and
then rehydrated. After the inactivation of endogenous
peroxidase with 0.3%H2O2 in methanol at room temperature
(RT) for 30 min, the slides were preincubated with 1% bovine
serum albumin (BSA) in PBS for 1 h to block nonspeciﬁc
reactions. The sections were then incubated with the primary
antibody (rabbit polyclonal anti-human IGFBP-3, -4, or -5
serum, mouse monoclonal anti-human IGF-I IgG or chicken
polyclonal anti-human IGF-I receptor IgY) (UBI, Lake Placid,
NY) overnight at RT. After washing four times with 0.075%
Brij in PBS, the slides were incubated with second antibody
[horseradish peroxidase (HRP)-conjugated goat anti-rabbit
IgG, HRP-conjugated goat anti-mouse IgG or HRP-conju-
gated rabbit anti-chicken IgY] for 1 h at RT. After washing
next with 0.075%Brij in PBS three times, the HRP sites were
visualized with 3,3#-diaminobenzidinetetrahydrochloride
(DAB) and H2O2, and counterstained with 2% methylgreen
as previously detailed20. As a negative control, rabbit
nonimmune serum, normal mouse IgG or normal chicken
IgY was used instead of the primary antibody. The
percentages of positive chondrocytes were determined by
counting the total number of chondrocytes over the area of
the surface, middle, and deep zones of the cartilage, which
contained between 70 and 500 cells with a mean of 152. Thesections were subsequently examined under a light micro-
scope (Olympus Provis AX 80) at a magniﬁcation of 400!
where ﬁve ﬁelds in the section were selected at random.
OLIGO-DNAs
The antisense oligo-DNA sequences which were com-
plementary to part of the sense sequences for human
IGFBP-321, -422 and -523 were selected as shown in Table
II. We also prepared oligo-DNA with 34 bases which was
complementary to part of the human 28S ribosomal RNA
Table I
Histologicalehistochemical grading system (Mankin et al.19)
Grade
I Structure
(a) Normal 0
(b) Surface irregularities 1
(c) Pannus and surface irregularities 2
(d) Clefts to transitional zone 3
(e) Clefts to radial zone 4
(f) Clefts to calciﬁed zone 5
(g) Complete disorganization 6
II Cells
(a) Normal 0
(b) Diffuse hypercellularity 1
(c) Cloning 2
(d) Hypocellularity 3
III Safranin-O staining
(a) Normal 0
(b) Slight reduction 1
(c) Moderate reduction 2
(d) Severe reduction 3
(e) No dye noted 4
IV Tidemark integrity
(a) Intact 0
(b) Crossed by blood vessels 1
Table II
The TeT dimerized oligo-DNA probe sequences of human IGFBPs
for in situ hybridization
Antisense oligo-DNA probe
IGFBP-3
5#: TTATTA-CGG TGT AGA TGC CGC ACG GCT GGC CCT
CGC TCA GTG CGC ACG TCA-ATTATT: 3#
IGFBP-4
5#: TTATTA-TCC TGG ATG GCC TCG ATC TCC GCC AGC
TCC ATG CAC ACG CCT-ATTATTATT: 3#
IGFBP-5
5#: TTATTA-CCC TGC TCA GAC TCC TGT CTC ATC TCA GGT
GCA GAG ATG ATC CGATTATTATT: 3#
Sense oligo-DNA probe
IGFBP-3
5#: TTATTA-TGA CGT GCG CAC TGA GCG AGG GCC AGC
CGT GCG GCA TCT ACA CCG-ATTATTATT: 3#
IGFBP-4
5#: TTATTA-AGG CGT GTG CAT GGA GCT GGC GGA GAT
CGA GGC CAT CCA GGA-ATTATTATT: 3#
IGFBP-5
5#: TTATTA-CGG ATC ATC TCT GCA CCT GAG ATG AGA
CAG GAG TCT GAG CAG GG-ATTATTATT: 3#
IGFBP; insulin-like growth factor binding protein; T-T; thymine-
thymine.
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assess the integrity and hybridizability of RNA in the
cartilage tissue sections. A computer-assisted search
(GenBank nucleic acid sequence database Release
110.0) of the selected oligo-DNA sequences (without the
ATT repeats) was conducted and no signiﬁcant homology
with any other published sequences was found.
LABELING OF OLIGO-DNAS
The oligo-DNAs were haptenized by ultraviolet-irradiation
to form thymineethymine (TeT) dimers as previously
detailed25.
DOT-BLOT HYBRIDIZATION
The procedures for dot-blot hybridization were previously
described24,26. Brieﬂy, 2 ml of the sense oligo-DNA solutions
were placed on nitrocellulose membranes that had been
pretreated with 20! SSC (1! SSCZ 0.15 M sodium
chloride and 0.015 M sodium citrate, pH 7.0) in a series of
spots from 1 pg to 10 ng per spot. The membranes were
hybridized at 42(C for 15e17 h with a 2 mg/ml TeTdimerized corresponding antisense or sense probe. After
washing once with 2! SSC, once with 1! SSC, and once
with 0.5! SSC, the membranes were immersed in blocking
solution [5% BSA, 100 mg/ml yeast transfer RNA (tRNA),
100 mg/ml salmon sperm DNA, 0.6 M NaCl, PBS and
500 mg/ml normal mouse IgG] for 1 h. Reaction with HRP
linked mouse anti-TeT IgG (Kyowa Medex, Japan, diluted
at 1:80 with the blocking solution) was performed for 3 h
and after washing with PBS the HRP sites were visualized
with DAB, H2O2, Co
2C, and Ni2C according to Adams27.
When TeT dimerized IGFBP antisense probes were
hybridized with IGFBP sense oligo-DNAs ﬁxed on a nitro-
cellulose ﬁlter, 10 pg of each oligo-DNA was detected.
However, no staining was found with the sense probe.
Similar results were obtained for the other probes, in-
dicating that the antisense probes were speciﬁc and
possessed adequate sensitivity for ISH studies.
IN SITU HYBRIDIZATION
ISH was performed as previously described26,28. Brieﬂy,
the sections were deparafﬁnized and rehydrated, and then
treated with 0.2 N HCl at RT for 20 min and digested
with 10 mg/ml of proteinase K at 37(C for 15 min. AfterFig. 1. IHC for the detection of IGFBP-3 (a, b, c), -4 (d, e, f), and -5 (g, h, i) for representative sections of control articular cartilage from a
74-year-old female. The zonal distribution of IGFBP immunostained chondrocytes is shown: superﬁcial layer (a, d, g), middle layer (b, e, h),
and deep layer (c, f, i). (Original magniﬁcation 200!.)
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immersed twice in 2 mg/ml glycine in PBS for 15 min and
kept in 40% deionized formamide in 4! SSC until being
used for hybridization. Hybridization was carried out at
37(C overnight with a 1e4 mg/ml TeT dimerized oligo-DNA
probe dissolved in hybridization medium composed of
10 mM TriseHCl (pH 7.4), 1 mM EDTA, 0.6 M NaCl, 1!
Denhardt’s solution, 250 mg/ml yeast tRNA, 125 mg/ml
salmon sperm DNA, and 40% deionized formamide. After
washing twice with 50% formamide in 0.5! SSC followed
by 50% formamide in 2! SSC three times at 37(C for 1 h
each time, the signals were detected using enzyme-IHC as
described above, without any counterstaining.
QUANTIFICATION OF ISH
We quantitatively analyzed the signal intensity of ISH with
an image analyzer (AXIOVISION Application version
2.0.5.3, Carl Zeiss Vision GmbH) connected to a Carl Zeiss
CCD camera (AxioCam). The images were transformed into
a matrix of 650! 514 pixels per frame with each pixelhaving one of 256 gray levels ranging from 0 corresponding
to black to 255 corresponding to absolute white. The
frequencies of positive cells for each IGFBP mRNA, which
were determined as the number of cells stained with the
antisense probe divided by the levels of staining with the
sense control probe, were measured using the public
domain Scion Image analysis program (Scion Corporation,
Maryland, USA). The number of positive chondrocytes was
counted by examining at least 100 chondrocytes for each
surface, middle and deep zone of the cartilage, and the
frequency was expressed as a percentage.
STATISTICAL ANALYSIS
The data were expressed as meansG S.E.M. and
analyzed using the ManneWhitney U test by Statview-
J4.5 computer software (Abacus Concepts Inc., Berkeley,
USA). A P-value of less than 0.05 was considered to
indicate statistical signiﬁcance. Correlations between the
different parameters were calculated using Spearman’s
rank correlation coefﬁcient.Fig. 2. IHC for the detection of IGFBP-3 (a, b, c), -4 (d, e, f), and -5 (g, h, i) for representative sections of osteoarthritic cartilage from a 62-year-
old female. The zonal distribution of IGFBP immunostained chondrocytes is shown: superﬁcial layer (a, d, g), middle layer (b, e, h), and deep
layer(c, f, i). (Original magniﬁcation 200!.)
443Osteoarthritis and Cartilage Vol. 13, No. 5Fig. 3. IHC of IGF-I and the IGF-I receptor in representative sections of control articular cartilage from a 74-year-old female (A) and
osteoarthritic cartilage from a 62-year-old female (B). The zonal distribution of immunostained chondrocytes is shown: superﬁcial layer (a, d),
middle layer (b, e), and deep layer (c, f). (Original magniﬁcation 400!.)Results
HISTOLOGIC FINDINGS
The OA cartilage tissues were categorized with Mankin
scores ranging from 6 to 12 in the (average 8.6) based on
the degree of ﬁbrillation, clustering of cells, and loss of
Safranin-O staining. There were essentially no histologic
abnormalities in the control cartilage samples except for
Fig. 4. A histogram of the percentage of cells immunoreactive
against IGFBP-3, -4, and -5 in the control (nZ 10) and OA (nZ 10)
cartilage over all layers. The bars indicate the mean and S.E.M.
score and the P-values indicate the difference between the control
and OA cartilage calculated using the ManneWhitney U test.a decrease in Safranin-O staining in some cases. The
Mankin score for the control specimens ranged from 0 to 2
with an average of 0.7.
IMMUNOHISTOCHEMISTRY
Representative immunohistochemical staining for IGFBP-
3, -4, and -5 in the control and OA cartilage is shown in
Fig. 5. A histogram of the percentage of cells immunoreactive
against IGF-I and the IGF-I receptor in the control (nZ 10) and OA
(nZ 10) cartilage over all layers. The bars indicate the mean and
S.E.M. score and the P-values indicate the difference between the
control and OA cartilage calculated using the ManneWhitneyU test.
444 H. Iwanaga et al.: IGF-binding proteins in osteoarthritisFigs. 1 and 2, for which the expression of IGFBP-3, -4, and -
5 in each layer of the cartilage, surface, middle and deep
zones was evaluated. IGFBP-3, -4 and -5 were found in the
cytoplasm of chondrocytes in all layers in the normal and
OA cartilage, while more intense signals and an increased
number of positive chondrocytes for these three IGFBPs
was found in the OA cartilage. In addition, staining of the
cartilage matrix for IGFBP-3 seemed to be increased, while
that for IGFBP-4 or -5 was nearly constant. When adjacent
sections were reacted with normal rabbit serum instead of
primary antibody, no staining was observed (data not
shown).
Representative immunohistolocalization of IGF-I and the
IGF-I receptor in the cartilage is shown in Fig. 3. For the
control cartilage, chondrocytes stained for IGF-I or the IGF-I
receptor were especially numerous in the surface layer,
whereas staining was seldom observed in the middle and
deep layers [Fig. 3(A)]. For the OA cartilage, an increased
number cells stained for IGF-I or the IGF-I receptor wasnoted for the surface layer, and some chondrocytes were
also stained in the middle and deep layers [Fig. 3(B)].
The percentages of positive chondrocytes for IGFBP-3,
-4, and -5 were evaluated for all layers of the samples for
the control (nZ 10) and OA cartilage (nZ 10) (Fig. 4). The
percentage of cells immunostained for IGFBP-3, -4, and -5
was signiﬁcantly higher for the OA cartilage compared to
the control (PZ 0.01, PZ 0.02, PZ 0.04, respectively).
Likewise, the percentages of positive chondrocytes immu-
nostained for IGF-I or the IGF-I receptor were evaluated for
all layers for samples from the control (nZ 10) and OA
cartilage (nZ 10) (Fig. 5). The percentage of cells
immunostained for IGF-I or the IGF-I receptor was
signiﬁcantly higher for the OA cartilage compared to the
control (PZ 0.001, PZ 0.005, respectively). Additionally,
we compared these ﬁndings to the histological Mankin
scores for cartilage lesions. Positive relationships were
found between the Mankin score and the percentage of
immunostained cells for IGFBP-3, 4, and -5 (rZ 0.74,Fig. 6. The relationship between the Mankin score and IGFBP-3 (A), IGFBP-4 (B), IGFBP-5 (C), IGF-I (D), and IGF-I (E). The Spearman’s rank
correlation coefﬁcient and P-value are also shown.
445Osteoarthritis and Cartilage Vol. 13, No. 5rZ 0.64, rZ 0.60, respectively). Also, IGF-I and the IGF-I
receptor were found to be correlated with the histological
score (rZ 0.77, rZ 0.64, respectively) (Fig. 6).
ISH ANALYSIS FOR IGFBP-3, -4, OR -5 MRNA EXPRESSION
Representative results of ISH for the control and the OA
cartilage are shown in Figs. 7 and 8. Although the signal
intensities for IGFBP-3, -4, or -5 mRNA varied among the
specimens, IGFBP-3, -4, and -5 mRNA were expressed in
all layers of the cartilage tissue. Compared to the control
cartilage, the expression of IGFBP-3, -4 and -5 mRNA was
increased in all layers of the chondrocytes for the OA
Cartilage. As a positive control, when a section was
hybridized with TeT dimerized 28S rRNA, signals were
observed in chondrocytes in all zones of the OA and control
cartilage (data not shown). As a negative control, when
a section was hybridized with TeT dimerized sense probes,
no signals were observed (data not shown).
When the percentages of chondrocytes expressing
IGFBP-3, -4, and -5 mRNA per total cells were evaluated
for the control (nZ 5, mean age of 77, range of 68 to of 85,
Mankin score average of 1) and OA cartilage (nZ 6, mean
age of 51, range of 43 to 62, Mankin score average of 8.5)(Fig. 9), the expression of IGFBP-3, -4, and -5 mRNA was
signiﬁcantly increased in the OA cartilage compared to that
of the control specimens (P! 0.01, P! 0.01, and
P! 0.02 respectively), and this was consistent with result
for the immunohistochemical study.
Discussion
In this study, we investigated the expression of IGFBP-3,
-4, and -5 at the protein and mRNA levels in OA cartilage,
and found that the expression of these proteins was
signiﬁcantly increased in OA cartilage compared to that of
the control. Also increases in the expression of IGF-I and
the IGF-I receptor were immunohistochemically conﬁrmed
for the OA cartilage. These ﬁndings in part suggest that any
disorder in the maintenance of cartilage in the OA speci-
mens was not due to a decrease in IGF-I or the IGF-I
receptor. Locally produced IGFBPs act as autocrine/para-
crine regulators of IGF activity in a positive and negative
manner. The inhibitory effect of IGFBPs is mediated via the
blocking of IGF binding to the IGF receptor. On the other
hand, IGFBPs on the cell surface or in the extracellular
matrix increase the local concentration of IGFs, thereby,Fig. 7. ISH in representative sections of control cartilage from a 74-year-old female. ISH was carried out using TeT dimerized IGFBP-3 (a, b,
c), -4 (d, e, f) or -5 (g, h, i) antisense probes. The zonal distributions of IGFBP mRNA expression of are shown: surface layer (a, d, g), middle
layer (b, e, h), and deep layer (c, f, i). (Original magniﬁcation 200!.)
446 H. Iwanaga et al.: IGF-binding proteins in osteoarthritisFig. 8. ISH in representative sections of osteoarthritic cartilage from a 62-year-old female. ISH was carried out using TeT dimerized IGFBP-3
(a, b, c), -4, (d, e, f) or -5 (g, h, i) antisense probes. The zonal distributions of IGFBP mRNA expression of are shown: surface layer (a, d, g),
middle layer (b, e, h), and deep layer (c, f, i). (Original magniﬁcation 200!.)potentiating this IGF activity. Furthermore, some IGFBPs
also act independently of IGFs29. In a previous study, we
showed that the binding of IGF-I to cells is displaced by
IGFBP-3 and IGFBP-530, suggesting that the enhanced
expression of IGFBPs in OA cartilage results in the
neutralization of IGF-1 activity. However, further studies
are needed to clarify these mechanisms.
Although Olney et al. showed the existence of IGFBP-2,
-3 and -4 but not IGFBP-5 in the conditioned medium of
normal human chondrocytes in vitro31, IGFBP-5 was
detected at the almost the same level as IGFBP-3 and -4
in our study. To explain this discrepancy, it is possible that
human chondrocytes also produce IGFBP-5 in vitro, but that
IGFBP-5 produced in the medium might be degraded by an
IGBFP-5 protease. The presence of an IGFBP-5 protease
has been identiﬁed in the medium of chondrocytes32,33. In
contrast, it was reported that the inhibition of IGFBP-5
proteolysis in joint ﬂuid increases IGFBP-534, which leads to
the improvement of OA.
IGF-I increases the production of IGFBP-3, -4 and -5 by
chondrocytes30,35, and the up-regulation of IGF-I mRNA
and IGF-I protein in the surface area of ﬁbrillated OA
cartilage has also been reported9. These ﬁndings suggest
that the increased level of IGF-I secreted by chondrocytesFig. 9. A histogram of the percentage of chondrocytes expressing
IGFBP-3, -4, and -5 mRNA evaluated over all zones for samples
from the control (nZ 5) and OA cartilage (nZ 6). The bars indicate
the mean and S.E.M. score and the P-values indicate the difference
between the control and OA cartilage calculated using the
ManneWhitney U test.
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autocrine/paracrine mechanism in the OA tissues.
Various factors known regulate the production of IGFBPs.
Increased IGFBP-3 levels in articular cartilage were also
immunohistochemically observed for estrogen treated
monkeys36. Inﬂammatory cytokines such as IL-1a or TNF-a
increase the production of IGFBP-3 or -5 by chondro-
cytes31, and prostaglandin E2 also increases the expres-
sion of IGFBP-3 and -437,38. These cytokines are elevated
in inﬂammatory diseases such as Rheumatoid Arthritus
(RA) and OA, and play roles in the destruction of cartilage
tissue in OA. Furthermore, IL-1b and TNF-a have been
immunodetected on the surface39 and in the middle and
deep layers40 of OA cartilage. Therefore, these cytokines
may exert degenerative effect on cartilage through the
enhanced expression of IGFBPs in OA tissue.
The increased level of IGFBP-3 in OA cartilage was also
seen by directly analyzing cartilage tissue extract41 or by
quantifying locally synthesized IGFBP-3 from cartilage
explants42. However, little is known about the localization
of IGFBPs in human articular cartilage, as only IGFBP-3
was identiﬁed in the chondrocyte territorial matrix together
with ﬁbronectin43,44. This complex of IGFBP-3 and ﬁbro-
nectin stores IGF-I in the chondrocyte territorial matrix,
which helps maintain a relatively constant level of IGF-I. In
this study, we found that expression of the IGF-I receptor
was signiﬁcantly increased in OA cartilage and was
correlated with the histological degeneration score. These
results are consistent with the ﬁndings of Middleton et al.10,
showing increased expression of IGF-I receptor mRNA in
OA cartilage and the highest level in advanced lesions by
means of ISH. On the other hand, similar levels of IGF-I
receptor mRNA in normal and OA chondrocytes were
reported by Tardif et al. using quantitative RT-PCR11.
These discrepancies might have occurred due to the stage
of OA45 or the age of the patients. Allowing for the fact that
the mean age of patients in control group was higher than
those in OA group in this study, there is still room for
argument of the results.
In conclusion, we found that the expression of IGFBP-3, 4
and -5 was signiﬁcantly increased in OA cartilage as well as
is IGF-I and the IGF-I receptor compared with that of control
cartilage. Moreover, the enhanced expression was signif-
icantly correlated with the histological changes in the
lesions. These results indicate that IGFBPs locally pro-
duced by chondrocytes may play a role in the pathogenesis
of OA.
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